Clinical Autonomic Research

, Volume 26, Issue 2, pp 97–105 | Cite as

Supine hypertension in Parkinson’s disease and multiple system atrophy

  • Alessandra Fanciulli
  • Georg Göbel
  • Jean Pierre Ndayisaba
  • Roberta Granata
  • Susanne Duerr
  • Stefano Strano
  • Carlo Colosimo
  • Werner Poewe
  • Francesco E. Pontieri
  • Gregor K. Wenning
Research Article



Supine hypertension (SH) is a feature of cardiovascular autonomic failure that often accompanies orthostatic hypotension and may represent a negative prognostic factor in parkinsonian syndromes. Here we investigated the frequency rate as well as the clinical and tilt test correlates of SH in Parkinson’s disease (PD) and multiple system atrophy (MSA).


197 PD (33 demented) and 78 MSA (24 MSA-Cerebellar, 54 MSA-Parkinsonian) patients who had undergone a tilt test examination were retrospectively included. Clinical-demographic characteristics were collected from clinical records at the time of the tilt test examination.


SH (>140 mmHg systolic, >90 mmHg diastolic) occurred in 34 % of PD patients (n = 66, mild in 71 % of patients, moderate in 27 %, severe in 2 %) and 37 % of MSA ones (n = 29, mild in 55 % of patients, moderate in 17 %, severe in 28 %). No difference was observed in SH frequency between demented versus gender-, age- and disease duration-matched non-demented PD patients, or between patients with the parkinsonian (MSA-P) versus the cerebellar (MSA-C) variant of MSA. In PD, SH was associated with presence of cardiovascular comorbidities (p = 0.002) and greater systolic (p = 0.007) and diastolic (p = 0.002) orthostatic blood pressure fall. Orthostatic hypotension (p = 0.002), and to a lesser degree, lower daily dopaminergic intake (p = 0.01) and use of anti-hypertensive medications (p = 0.04) were associated with SH in MSA.


One-third of PD and MSA patients suffer from mild to severe SH, independently of age, disease duration or stage. In PD, cardiovascular comorbidities significantly contribute to the development of SH, while in MSA, SH appears to reflect cardiovascular autonomic failure.


Parkinson’s disease Parkinson’s disease with dementia Multiple system atrophy Orthostatic hypotension Supine hypertension 


Study funding

This was an academic study; no external financial support was allotted.

Compliance with ethical standards

Competing interests

A Fanciulli: reports no competing interests related to this article. Dr. Fanciulli received royalties from Springer Verlag and from the Massachusetts Medical Society. G. Göbel: reports no competing interests. J. P. Ndayisaba: reports no competing interests. R. Granata: reports no competing interests. S. Duerr: reports no competing interests. S. Strano: reports no competing interests. C. Colosimo: reports no competing interests related to this article. Prof Colosimo served as consultant for Ipsen, Merz and Lundbeck. W. Poewe: reports no competing interests related to this article. Unrelated to this research he reports personal fees from AbbVie, Allergan, AstraZeneca, BIAL; Boehringer-Ingelheim, Boston Scientific, GlaxoSmithKline, Ipsen, Lundbeck, Medtronic, MSD, Merck-Serono, Merz Pharmaceuticals, Novartis, Orion Pharma, Teva, UCB and Zambon (consultancies and lecture fees in relation to clinical drug development programmes for PD). Royalties: Thieme, Wiley Blackwell, Oxford University Press and Cambridge University Press. F. E. Pontieri: reports no competing interests. G.K.Wenning: reports no competing interests related to this article. Prof. Wenning served as consultant for Astra Zeneca, received lecture fees from Astra, Lundbeck, UCB and Abbvie and royalties from Cambridge University Press, Springer Verlag and from the Massachusetts Medical Society.

Ethical approval

The study received approval by the local ethical committees and was performed according to the Declaration of Helsinki.

Informed consent

For this type of study informed consent is not required.

Supplementary material

10286_2015_336_MOESM1_ESM.doc (117 kb)
Supplementary material 1 (DOC 117 kb)


  1. 1.
    Freeman R et al (2011) Consensus statement on the definition of orthostatic hypotension, neurally mediated syncope and the postural tachycardia syndrome. Clin Auton Res 21(2):69–72CrossRefPubMedGoogle Scholar
  2. 2.
    Schroeder C, Jordan J, Kaufmann H (2013) Management of neurogenic orthostatic hypotension in patients with autonomic failure. Drugs 73(12):1267–1279CrossRefPubMedGoogle Scholar
  3. 3.
    Velseboer DC et al (2011) Prevalence of orthostatic hypotension in Parkinson’s disease: a systematic review and meta-analysis. Parkinsonism Relat Disord 17(10):724–729CrossRefPubMedGoogle Scholar
  4. 4.
    Fanciulli A, Wenning GK (2015) Multiple-system atrophy. N Engl J Med 372(3):249–263CrossRefPubMedGoogle Scholar
  5. 5.
    Wenning GK et al (2013) The natural history of multiple system atrophy: a prospective European cohort study. Lancet Neurol 12(3):264–274Google Scholar
  6. 6.
    Low PA et al (2015) Natural history of multiple system atrophy in the USA: a prospective cohort study. Lancet Neurol 14(7):710–719Google Scholar
  7. 7.
    Fanciulli A et al (2014) Detecting nocturnal hypertension in Parkinson’s disease and multiple system atrophy: proposal of a decision-support algorithm. J NeurolGoogle Scholar
  8. 8.
    Plaschke M et al (1998) Twenty-four-hour blood pressure profile and blood pressure responses to head-up tilt tests in Parkinson’s disease and multiple system atrophy. J Hypertens 16(10):1433–1441CrossRefPubMedGoogle Scholar
  9. 9.
    Jordan J et al (1999) Contrasting effects of vasodilators on blood pressure and sodium balance in the hypertension of autonomic failure. J Am Soc Nephrol 10(1):35–42PubMedGoogle Scholar
  10. 10.
    Fanciulli A et al (2013) The potential prognostic role of cardiovascular autonomic failure in alpha-synucleinopathies. Eur J Neurol 20(2):231–235CrossRefPubMedGoogle Scholar
  11. 11.
    Kim JS et al (2012) Association of cognitive dysfunction with neurocirculatory abnormalities in early Parkinson disease. Neurology 79(13):1323–1331CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Pilleri M et al (2013) Cognitive and MRI correlates of orthostatic hypotension in Parkinson’s disease. J Neurol 260(1):253–259CrossRefPubMedGoogle Scholar
  13. 13.
    Oh YS, Kim JS, Lee KS (2013) Orthostatic and supine blood pressures are associated with white matter hyperintensities in Parkinson disease. J Mov Disord 6(2):23–27CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Lim TS et al (2009) White matter hyperintensities in patients with multiple system atrophy. J Neurol 256(10):1663–1670CrossRefPubMedGoogle Scholar
  15. 15.
    Jones JD et al (2014) Influence of hypertension on neurocognitive domains in nondemented Parkinson’s disease patients. Parkinsons Dis 2014:507529PubMedPubMedCentralGoogle Scholar
  16. 16.
    Anang JB et al (2014) Predictors of dementia in Parkinson disease: a prospective cohort study. Neurology 83(14):1253–1260CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Biaggioni I, Robertson RM (2002) Hypertension in orthostatic hypotension and autonomic dysfunction. Cardiol Clin 20(2):291–301 (vii) CrossRefPubMedGoogle Scholar
  18. 18.
    Shannon J et al (1997) The hypertension of autonomic failure and its treatment. Hypertension 30(5):1062–1067CrossRefPubMedGoogle Scholar
  19. 19.
    Pavy-Le Traon A et al (2015) New insights into orthostatic hypotension in multiple system atrophy: a European multicentre cohort study. J Neurol Neurosurg Psychiatry (e-pub ahead of print)Google Scholar
  20. 20.
    Schutzman J et al (1994) Head-up tilt and hemodynamic changes during orthostatic hypotension in patients with supine hypertension. J Am Coll Cardiol 24(2):454–461CrossRefPubMedGoogle Scholar
  21. 21.
    Chobanian AV et al (2003) Seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure. Hypertension 42(6):1206–1252CrossRefPubMedGoogle Scholar
  22. 22.
    Hughes AJ et al (2001) What features improve the accuracy of clinical diagnosis in Parkinson’s disease: a clinicopathologic study. 1992. Neurology. 57(10 Suppl 3):S34–S38PubMedGoogle Scholar
  23. 23.
    Emre M et al (2007) Clinical diagnostic criteria for dementia associated with Parkinson’s disease. Mov Disord 22(12):1689–1707 CrossRefPubMedGoogle Scholar
  24. 24.
    Gilman S et al (2008) Second consensus statement on the diagnosis of multiple system atrophy. Neurology 71(9):670–676CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Tomlinson CL et al (2010) Systematic review of levodopa dose equivalency reporting in Parkinson’s disease. Mov Disord 25(15):2649–2653CrossRefPubMedGoogle Scholar
  26. 26.
    Benjamini Y, Hochberg Y (1995) Controlling the false discovery rate: a practical and powerful approach to multiple testing. J Roy Stat Soc B 57(1):289–300Google Scholar
  27. 27.
    Rose KM et al (2000) Orthostatic hypotension and the incidence of coronary heart disease: the Atherosclerosis risk in communities study. Am J Hypertens 13(6 Pt 1):571–578CrossRefPubMedGoogle Scholar
  28. 28.
    Fedorowski A et al (2010) Orthostatic hypotension predicts incidence of heart failure: the Malmo preventive project. Am J Hypertens 23(11):1209–1215CrossRefPubMedGoogle Scholar
  29. 29.
    Goldstein DS et al (2003) Association between supine hypertension and orthostatic hypotension in autonomic failure. Hypertension 42(2):136–142CrossRefPubMedGoogle Scholar
  30. 30.
    Benarroch EE, Schmeichel AM, Parisi JE (2003) Preservation of branchimotor neurons of the nucleus ambiguus in multiple system atrophy. Neurology 60(1):115–117CrossRefPubMedGoogle Scholar
  31. 31.
    Benarroch EE et al (2006) Involvement of vagal autonomic nuclei in multiple system atrophy and Lewy body disease. Neurology 66(3):378–383CrossRefPubMedGoogle Scholar
  32. 32.
    Benarroch EE (2003) Brainstem in multiple system atrophy: clinicopathological correlations. Cell Mol Neurobiol 23(4–5):519–526CrossRefPubMedGoogle Scholar
  33. 33.
    Davies B et al (1982) Increased numbers of alpha receptors in sympathetic denervation supersensitivity in man. J Clin Invest 69(4):779–784CrossRefPubMedPubMedCentralGoogle Scholar
  34. 34.
    Hohler AD et al (2012) Differences in motor and cognitive function in patients with Parkinson’s disease with and without orthostatic hypotension. Int J Neurosci 122(5):233–236CrossRefPubMedGoogle Scholar
  35. 35.
    Allcock LM et al (2006) Orthostatic hypotension in Parkinson’s disease: association with cognitive decline? Int J Geriatr Psychiatry 21(8):778–783CrossRefPubMedGoogle Scholar
  36. 36.
    Peralta C et al (2007) Orthostatic hypotension and attention in Parkinson’s disease with and without dementia. J Neural Transm 114(5):585–588CrossRefPubMedGoogle Scholar
  37. 37.
    Wenning GK et al (2012) Orthostatic hypotension is differentially associated with the cerebellar versus the parkinsonian variant of multiple system atrophy: a comparative study. Cerebellum 11(1):223–226CrossRefPubMedGoogle Scholar
  38. 38.
    Vanacore N et al (2000) Smoking habits in multiple system atrophy and progressive supranuclear palsy. European Study Group on Atypical Parkinsonisms. Neurology 54(1):114–119CrossRefPubMedGoogle Scholar
  39. 39.
    Allam MF et al (2004) Smoking and Parkinson’s disease: systematic review of prospective studies. Mov Disord 19(6):614–621CrossRefPubMedGoogle Scholar
  40. 40.
    Kollensperger M et al (2010) Presentation, diagnosis, and management of multiple system atrophy in Europe: final analysis of the European multiple system atrophy registry. Mov Disord 25(15):2604–2612CrossRefPubMedGoogle Scholar
  41. 41.
    Gilman S et al (2005) The North American multiple system atrophy study group. J Neural Transm 112(12):1687–1694CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2016

Authors and Affiliations

  • Alessandra Fanciulli
    • 1
    • 2
  • Georg Göbel
    • 3
  • Jean Pierre Ndayisaba
    • 1
  • Roberta Granata
    • 1
  • Susanne Duerr
    • 1
  • Stefano Strano
    • 4
  • Carlo Colosimo
    • 5
  • Werner Poewe
    • 1
  • Francesco E. Pontieri
    • 2
    • 6
  • Gregor K. Wenning
    • 1
  1. 1.Department of NeurologyMedical University of InnsbruckInnsbruckAustria
  2. 2.Department of Neuroscience, Mental Health and Sensory Organs“Sapienza” University of RomeRomeItaly
  3. 3.Department of Medical Statistics, Informatics and Health EconomicsMedical University of InnsbruckInnsbruckAustria
  4. 4.Department of Heart and Great Vessels “A. Reale”“Sapienza” University of RomeRomeItaly
  5. 5.Neurology and Stroke Unit, Department of Neurosciences, Azienda OspedalieroUniversitaria Santa MariaTerniItaly
  6. 6.I.R.C.C.S Santa Lucia FoundationRomeItaly

Personalised recommendations